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AbstrACt
Introduction Haemophilia A is an inherited bleeding disorder 
characterised by factor VIII (FVIII) deficiency. In patients with 
non-severe haemophilia A, surgery and bleeding are the 
main indications for treatment with FVIII concentrate. A recent 
study reported that standard dosing frequently results in FVIII 
levels (FVIII:C) below or above FVIII target ranges, leading to 
respectively a bleeding risk or excessive costs. In addition, 
FVIII concentrate treatment carries a risk of development of 
neutralising antibodies. An alternative is desmopressin, which 
releases endogenous FVIII and von Willebrand factor. In most 
patients with non-severe haemophilia A, desmopressin alone 
is not enough to achieve FVIII target levels during surgery or 
bleeding. We hypothesise that combined pharmacokinetic 
(PK)-guided administration of desmopressin and FVIII 
concentrate may improve dosing accuracy and reduces FVIII 
concentrate consumption.
Methods and analysis In the DAVID study, 50 patients 
with non-severe haemophilia A (FVIII:C ≥0.01 IU/mL) with 
a bleeding episode or undergoing surgery will receive 
desmopressin and FVIII concentrate combination treatment. 
The necessary dose of FVIII concentrate to reach FVIII target 
levels after desmopressin administration will be calculated 
with a population PK model. The primary endpoint is the 
proportion of patients reaching FVIII target levels during the 
first 72 hours after start of the combination treatment. This 
approach was successfully tested in one pilot patient who 
received perioperative combination treatment.
Ethics and dissemination The DAVID study was 
approved by the medical ethics committee of the 
Erasmus MC. Results of the study will be communicated 
trough publication in international scientific journals and 
presentation at (inter)national conferences.
trial registration number NTR5383; Pre-results.
IntroduCtIon  
Haemophilia A is an X-linked bleeding 
disorder characterised by a factor VIII (FVIII) 
deficiency. Patients with non-severe haemo-
philia A (FVIII:C ≥0.01 IU/mL) suffer from 
bleeding in the perioperative setting and 
after (minor) trauma. Treatment consists of 
either desmopressin or FVIII concentrate.
FVIII concentrate is an effective but expen-
sive treatment option. With current dosing 
based on body weight, baseline FVIII:C and 
target FVIII:C, FVIII:C both below (7%–45%) 
and above (32%–81%) FVIII target levels have 
been observed.1 2 FVIII:C below target may 
lead to an increased bleeding risk, whereas 
levels above target increase the costs. Exces-
sively high FVIII:C may also be associated with 
thrombosis.3–5 In addition, high FVIII concen-
trate doses may induce the development of 
FVIII neutralising antibodies, causing ineffec-
tiveness of treatment with FVIII concentrate. 
In cases where antibodies cross-react with 
strengths and limitations of this study
 ► The DAVID-study is a multicentre, prospective trial 
including patients from eight haemophilia treatment 
centres in the Netherlands.
 ► Desmopressin and factor VIII (FVIII) concentrate 
combination treatment is an innovative treatment 
option for patients with non-severe haemophilia A.
 ► By using maximum a posteriori Bayesian estimation 
based on an integrated population pharmacokinetic 
model and measured FVIII levels, the dosing of FVIII 
concentrate may be improved, with less FVIII levels 
above and below target.
 ► The DAVID study is a single-armed trial.
 ► The study population is heterogeneous as all types 
of surgery and bleeding episodes may be included.
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patient’s endogenous FVIII, they can even cause a severe 
phenotype with spontaneous bleeding.6–8 Therefore, 
dosing within the target range with restriction of FVIII 
concentrate use is important.
An alternative to FVIII concentrate is desmopressin, 
a synthetic analogue of vasopressin. It releases von Will-
ebrand factor (VWF) from the endothelium and FVIII, 
thereby improving haemostasis.9–11 Although treatment 
is often effective, FVIII:C response to desmopressin 
exhibits a high variability between patients with haemo-
philia A. Contributing factors reported in the literature 
are age, baseline FVIII:C and the F8-gene mutation.12–14 
However, these factors do not explain the observed vari-
ability entirely. In addition, in most patients, FVIII:C 
does not increase sufficiently to prevent perioperative 
bleeding.
Other limitations of desmopressin are the experi-
enced side effects and tachyphylaxis. Most side effects 
are mild and transient, such as vasodilation. More severe 
side effects like hyponatraemia are rare and can usually 
be prevented by a fluid restriction.15 Tachyphylaxis occurs 
when repeated dosages of desmopressin are given with 
short time intervals (12–24 hours). The decrease in 
FVIII:C response is approximately 30% from the second 
dose onwards in case of a 24-hour interval and is believed 
to be caused by a temporary depletion of VWF and FVIII 
from the endothelium.16
Combined administration of desmopressin and FVIII 
concentrate may be able to overcome several of the draw-
backs of both separate treatment options. However, there 
is a lack of experience and knowledge with regard to 
the efficacy and safety of combination treatment. More-
over, optimisation of dosing is necessary to get and keep 
FVIII:C within the target range.
A valuable approach could be pharmacokinetic 
(PK)-guided dosing, where FVIII:C responses of future 
dosages are predicted based on a population PK model 
in combination with a limited number (two to three) of 
FVIII:C measurements, obtained after administration of 
desmopressin and/or FVIII concentrate. This technique 
was previously shown to be effective in both the prophy-
lactic and perioperative setting in patients with severe 
and moderate haemophilia A.17 18 A prospective trial 
using PK-guided dosing in the perioperative treatment 
of patients with moderate and severe haemophilia A is 
ongoing.19
Therefore, we hypothesise that combined PK-guided 
dosing of desmopressin and FVIII concentrate may 
be a feasible treatment option in patients with non-se-
vere haemophilia A with a bleeding episode or under-
going surgery. Our aim is to show that the proportion of 
patients with FVIII:C within the FVIII target ranges can be 
increased by the use of the combination treatment and 
PK-guided dosing. In addition, the consumption of FVIII 
concentrate will be reduced. This innovative approach in 
haemophilia treatment may be a promising alternative 
with an increase in quality of care and a concomitant cost 
reduction.
MEthods And AnAlysIs
objectives
The primary objective of the DAVID study is to evaluate 
if combination treatment of desmopressin and PK-guided 
dosing of FVIII concentrate is able to increase the propor-
tion of patients with non-severe haemophilia A with 
FVIII:C within the target range during the first 72 hours 
after start of combination treatment compared with 
historical controls.
Secondary objectives
1. To assess FVIII concentrate consumption in all patients.
2. To acquire data to improve the integrated population 
PK model for desmopressin and FVIII concentrate 
combination treatment.
3. To establish (possible) adverse events of combination 
treatment, for example, side effects of desmopressin, 
bleeding episodes, development of neutralising anti-
bodies and thrombotic events.
4. To evaluate the extent of tachyphylaxis after desmo-
pressin treatment.
5. To perform an economical evaluation to quantify the 
potential cost reduction of the combination treatment.
6. To evaluate the experienced quality of patient care.
design
The DAVID study is a multicentre single-arm trial in 
patients with non-severe haemophilia A with a bleeding 
episode or in need of a surgical procedure. The study 
was designed by a project committee existing of members 
of all participating sites (see online supplementary data 
1 and 2). Patients will receive combination treatment 
of desmopressin and FVIII concentrate instead of the 
conventional treatment which consists of FVIII concen-
trate monotherapy.
Patient selection and recruitment
Patients with non-severe haemophilia A ≥12 years of age 
with a bleeding episode or undergoing a surgical proce-
dure, requiring FVIII replacement therapy and having 
a sufficient response to desmopressin, will be included. 
Patients will be recruited from one of the following haemo-
philia treatment centres in the Netherlands: Erasmus 
University Medical Centre Rotterdam, Academic Medical 
Centre Amsterdam, Leiden University Medical Centre, 
University Medical Centre Groningen, Radboud univer-
sity medical centre Nijmegen, University Medical Centre 
Utrecht, Maxima Medical Centre Eindhoven and Maas-
tricht University Medical Centre (see also online supple-
mentary data 2). They will be approached by telephone 
or during a visit to the (outpatient) clinic if they present 
with a bleeding or need a surgical procedure.
Inclusion criteria
 ► Patients with non-severe haemophilia A 
(FVIII:C≥0.01 IU/mL)
 ► Requiring a surgical procedure or having a bleeding 
episode
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 ► Requiring replacement therapy with FVIII concen-
trate for at least 48 hours
 ► Age between 12 and 70 years at study inclusion date
 ► (Parental) informed consent
 ► Results of a desmopressin test available (minimal 
absolute FVIII:C increase >0.2 IU/mL)
Exclusion criteria
 ► Patients with other congenital or acquired haemo-
static abnormalities
 ► Inadequate response to desmopressin (absolute 
increase in FVIII:C<0.2 IU/mL) during a previous 
desmopressin test
 ► FVIII neutralising antibodies (in medical history), 
unless successfully treated with immunotolerance 
induction therapy
 ► Initiation of FVIII concentrate treatment >24 hours 
before study inclusion
 ► Patients not eligible for desmopressin treatment 
due to contraindications, for example, intolerance, 
interactions with comedication or due to type of 
surgery
Interventions and study procedures
All patients will receive combination treatment of desmo-
pressin and FVIII concentrate during a bleeding episode 
or in the perioperative setting for at least 48 hours. All 
patients will receive a standard dose of desmopressin 
intravenously (0.3 µg/kg; no maximum dose). In order 
to combine both medication regimens, an individualised 
dosing advice for FVIII concentrate will be provided by 
the clinical pharmacologist. The initial dosing advice 
will be based on the FVIII:C response observed after a 
test administration of desmopressin (see below) and 
previously collected patient and population pharmacoki-
netic data after administration of desmopressin (endog-
enous FVIII) and FVIII concentrate (exogenous FVIII). 
The treating physician states the duration of combina-
tion treatment and the mode of administration of FVIII 
concentrate (continuous or intermittent administration) 
and determines FVIII target ranges. During combination 
treatment, FVIII:C will be assessed regularly. Accordingly, 
dose adjustments for FVIII concentrate will be made iter-
atively based on the results of a desmopressin test admin-
istration and using Bayesian analysis. Bayesian analysis 
will be performed with the NONMEM software using a 
dedicated integrated population model describing the 
PK of FVIII following both the administration of desmo-
pressin and FVII concentrate. As bleeding or acute 
surgery calls for immediate treatment and constructing 
a dosing advice takes time, a patient may be included in 
the DAVID study until 24 hours after the start of FVIII 
concentrate monotherapy.
Adherence to the study protocol will be improved by 
the use of a separate script per included patient, in which 
an approximated timeline, contact details and all respon-
sibilities of the involved research and treatment team are 
written down.
Concomitant treatment
As patients receive desmopressin, they will have a fluid 
restriction of 1.5 L per 24 hours, until 24 hours after 
the last desmopressin administration. Furthermore, all 
concomitant treatment and therapeutics are allowed, 
except for the therapeutics specified in the exclusion 
criteria. This means other treatment than desmopressin 
or factor concentrate necessary to prevent or treat 
bleeding, such as tranexamic acid, is allowed as well. The 
same will apply for prophylactic treatment to prevent 
thrombosis. These treatment options will be applied at 
the discretion of the treating physician and will be docu-
mented for all patients.
Desmopressin test administration
All patients must have undergone a desmopressin test 
with at least three FVIII:C measurements. If performed 
during childhood (<18 years), the test is only admissible 
when performed ≤4 years before study inclusion. When 
no desmopressin test has been performed meeting these 
criteria, the test should be performed with a standard 
intravenous desmopressin dose of 0.3 µg/kg infused over 
30 min with a minimum of three FVIII:C measurements: 
before the administration of desmopressin, around 1 hour 
after desmopressin administration for peak measure-
ment and at least one sample thereafter, for example, 
after 4 hours. All time points of blood sampling and end 
of desmopressin administration should be documented 
precisely, as well as exact desmopressin dose and duration 
of infusion.
PK-guided dosing
In order to provide an individualised dosing advice, a 
Bayesian analysis will be performed on the basis of an 
integrated population PK model. This population model 
has been constructed based on two population pharma-
cokinetic models: (1) a population PK model of FVIII:C 
response after desmopressin administration20 and (2) a 
population PK model of FVIII:C after administration of 
FVIII concentrate.20 This latter model was constructed 
based on perioperative data from 29 adults patients 
with non-severe haemophilia A from whom 245 FVIII:C 
measurements were available. The final model esti-
mated the baseline FVIII:C to which estimated FVIII:C, 
that followed administration of FVIII concentrate, were 
added according to a one-compartment model with 
first-order elimination. Two covariates could be identi-
fied after multivariate regression analysis: VWF:Ag had a 
negative association with clearance and the most recently 
measured FVIII:C had a positive association with the esti-
mated baseline. In table 1, the most important model 
characteristics are shown.
The integrated population PK model, used in this 
study, describes the average PK, including the variability 
of the baseline FVIII:C and FVIII:C response between 
and within patients following both the administration of 
desmopressin and the administration of FVIII concen-
trate. This model will be used for both the perioperative 
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setting and around bleeding episodes. The individualised 
dosing advice for the first dose of FVIII concentrate will be 
provided based on this model along with the results of the 
desmopressin test administration and the perioperative 
FVIII target levels. Further dosing of FVIII concentrates 
will be adjusted daily by iterative maximum a posteriori 
Bayesian analysis based on the population PK model in 
conjunction with perioperatively measured FVIII:C. In 
this analysis, the following information will be included: 
(1) FVIII release in response to desmopressin after the 
test dose, (2) baseline FVIII:C and (3) measured FVIII:C 
(both trough and peak levels) (figure 1 and table 2). Dose 
adjustments based on this iterative Bayesian analysis will 
be performed in NONMEM software. All dosing advices 
will be given 1 day in advance.
Experienced quality of patient care
To assess experienced quality of care during this innova-
tive intervention, two questionnaires will be given to the 
patients. Side effects will be assessed using the question-
naire previously developed and used by Stoof et al.15 This 
questionnaire includes the occurrence of seven different 
self-reported side effects on a five-point scale and two on 
a 10-point scale. Side effects will be evaluated at two time 
points: before surgery and 3 days after surgery. In the 
second questionnaire (3 days after surgery), experienced 
quality of care will be evaluated with the addition of three 
questions dedicated to desmopressin and FVIII concen-
trate combination treatment. Patients will report their 
satisfaction with the combination treatment on a scale of 
1 to 100. They will have the opportunity to explain what Figure 1 Flowchart of study. FVIII, factor VIII.
Table 1 Model characteristics of the population PK model 
for FVIII concentrates
Parameter
Population 
estimate RSE (%)
Baseline FVIII:C (IU/mL) 0.211 10.9
Clearance (mL/h) 208 10
Volume of distribution (mL) 3400 4.9
Proportional error (%) 17.3 8.4
VWF:Ag on clearance −0.285 5.4
Most recent FVIII:C on 
baseline FVIII:C
0.891 15.8
IOV of baseline FVIII:C (%) 54.7 11.0
IIV of clearance (%) 37.4 19.7
IIV of volume of distribution 
(%)
20.8 26.8
 The covariate associations between VWF:Ag and clearance was 
modelled as a non-linear function, while the association between 
most recent FVIII:C and baseline FVIII:C was modelled as a linear 
function. The numbers for the covariate associations (−0.285 and 
0.891) describe both the shape and magnitude of the covariate 
effect: the more the number deviates from 0, the larger the effect of 
a covariate on the PK parameter.
IIV, interindividual variability; IOV, interoccasion variability; RSE, 
relative standard error; VWF:Ag, von Willebrand factor antigen.
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is needed to improve the given grade. Finally, they can 
state their preference for one of the treatment options: 
FVIII concentrate monotherapy or combination treat-
ment. The last question will only be asked to patients 
who have a previous experience with FVIII concentrate 
monotherapy.
sample size
In the DAVID study, the proportion of patients that reach 
FVIII target levels with combination treatment in the 
first 72 hours postoperatively (without adding off-pro-
tocol FVIII concentrates) will be assessed. Historical data 
on current FVIII treatment show a proportion of 0.3 of 
patients with non-severe haemophilia A with FVIII:C 
within target ranges in this time period.2 A doubling 
of this proportion, leading to a proportion of patients 
of 0.6, is believed to be clinically relevant. To study this 
with a power of 90% and a two-sided significance level 
of 0.05, a sample size of minimally 25 patients is needed. 
As different surgical procedures, both major and minor, 
may be performed on included patients and the baseline 
FVIII:C level may have a wide range (approximately 0.01–
0.60 IU/mL), the included patient population may be 
heterogeneous. In addition, patients may drop out during 
the perioperative treatment. This may, for example, 
be the case if patients are no longer eligible to receive 
desmopressin due to changed clinical status. However, 
no specific stopping criteria are present. To overcome 
both the heterogeneity and possible dropout, we aim to 
include 50 patients.
To reach our target sample size and ensure we do not 
miss any patients, all participating centres will be updated 
regularly by e-mail, newsletters and during meetings.
outcome measures
Primary outcome
The primary outcome will be the proportion of patients 
with FVIII trough levels within the FVIII target range 
during the first 72 hours after start of combination treat-
ment. If a patient has one trough level outside the target 
range or needs off-protocol FVIII concentrate within the 
first 72 hours of combination the treatment, the primary 
endpoint is not reached in that patient. Off-protocol 
FVIII concentrate is defined as all administered FVIII 
concentrate outside the PK-guided dosing advice as given 
by the clinical pharmacologist. FVIII:C will be targeted 
according to the Dutch Treatment Guideline (table 3).21 
The treating physician may deviate from the guideline 
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Table 3 Target ranges for factor VIII:C in IU/mL in the 
perioperative setting21
Time FVIII target level (IU/ml)
Day 0 (hour 0–24) 0.8–1.0 (peak)
Day 1–4 (hour 24–96) 0.5–0.8 (trough)
Day ≥5 (hour>96) 0.3–0.5 (trough)
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and set different target ranges, based on bleeding pheno-
type/history or type of surgery.
FVIII:C measurements will be performed with the 
one-stage assay. Each participating may use its own assay. 
However, all centres are certified and accredited.
Secondary outcomes
 ► FVIII concentrate consumption, expressed as the 
total amount of administered units of FVIII concen-
trate per kilogram per patient;
 ► Number and nature of adverse events during 
combined treatment;
 ► Incidence and severity of bleeding, where the severity 
of bleeding will be graded according to the Inter-
national Society on Thrombosis and Haemostasis 
(ISTH) criteria for major and minor bleeding22 23;
 ► Incidence of FVIII neutralising antibodies; measured 
with the Bethesda assay
 ► Incidence of thrombosis, where thrombosis will be 
defined according to the Dutch guidelines on throm-
bosis, myocardial infarctions and strokes24 25;
 ► Incidence and extent of tachyphylaxis, defined as a 
reduction in the absolute increase in FVIII:C after the 
second and third desmopressin infusion;
 ► Medical costs and an economic evaluation;
 ► Experience quality of patient care, measured by a 
questionnaire.
data analysis plan
All baseline characteristics will be described as means 
and SD or medians with IQR, dependent on whether the 
parameter is normally distributed. The primary outcome, 
the proportion of patients within FVIII target ranges, 
will be analysed by a χ2 test. Retrospective data will be 
used as a reference, as the DAVID study only has one 
study arm.2 PK data will be analysed using the NONMEM 
software package. Tachyphylaxis of FVIII:C response to 
desmopressin will be analysed with a paired t-test. Other 
secondary outcomes will be documented in a descriptive 
manner, except for the economic analysis.
Economic analysis
An economic evaluation will be performed from a health-
care perspective from the day of surgery to 90 days post-
operatively. The cost-effectiveness of combined treatment 
will be assessed by calculating the incremental cost-effec-
tiveness ratio (ICER), defined as the difference in costs of 
combined treatment, compared with usual care, divided 
by the average change in effectiveness. Actual medical 
costs will be calculated by multiplying the volumes of 
healthcare use with the corresponding unit prices. 
Perioperative data resource use (desmopressin, FVIII 
concentrates, additional FVIII:C and VWF measurements, 
PK profiling) will be collected from medical files. Usual 
medical costs (to compare to combination treatment 
costs) will be calculated based on a treatment protocol as 
it would have been without desmopressin use, taking into 
account patient’s body weight, baseline FVIII:C and type of 
surgery. The reduction in costs will be represented by the 
usual medical costs (units of FVIII concentrates) minus 
the actual medical costs for combined treatment (units 
of FVIII concentrates, µg of desmopressin, extra FVIII:C 
measurements). An additional sensitivity analysis will be 
performed to assess the stability of the results to changes 
in costs and effectiveness parameters. The primary effec-
tiveness parameter is the proportion of patients reaching 
FVIII target levels with desmopressin and FVIII concen-
trate combination treatment. The secondary effective-
ness parameter is the frequency of adverse events during 
combination treatment.
Patient and public involvement
During the development of this study, we worked closely 
together with the Netherlands Haemophilia Patient 
Society (NVHP). One representative of the NVHP is 
member of the project committee and helped us with 
the study design. Moreover, five members of the NVHP 
were invited to comment on the patient information. 
The design and information were adjusted according 
to their opinions and questions. The final results of the 
DAVID study will be communicated through scientific 
international journals and at international conferences. 
One major conference may be that of the World Feder-
ation of Haemophilia, attended by both physicians, 
researchers and patients from all over the world. In addi-
tion, the results will be communicated in the magazine 
of the NVHP. Finally, results will also be implemented in 
the treatment guidelines and patient information will be 
adjusted accordingly.
Proof of concept
As a proof of concept, we present one case of a patient 
that was treated with desmopressin and FVIII concentrate 
combination treatment for the duration of 24 hours. This 
patient has signed a BMJ consent form to publish his infor-
mation in this manuscript. The patient was a 53-year-old 
man with moderate haemophilia A (FVIII:C 0.04 IU/
ml). His body weight was 100 kg. He was in need of dental 
surgery and needed treatment to prevent bleeding. He 
received an infusion of desmopressin (0.3 µg/kg) over 
30 min, followed 30 min later by FVIII concentrate in a 
dose of 25 IU/kg (2500 IU). He received a second dose of 
FVIII concentrate (20 IU/kg; i.e. 2000 IU) in the evening 
to maintain his FVIII:C above target values. Both FVIII 
concentrate dosages were determined using the inte-
grated PK model and based on the patient’s response 
to a previous desmopressin dose and a previous FVIII 
concentrate administration. Figure 2 shows the measured 
FVIII:C and the FVIII:C as predicted by the integrated PK 
model. All measured FVIII:C levels were within 0.10 IU/
mL of the predicted levels (figure 2). The patient only 
had mild side effects of desmopressin, that is, flushing 
and mild tachycardia (101 bpm). To prevent bleeding, he 
was also treated with tranexamic acid for multiple days. 
No bleeding was reported before and after the surgery. 
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However, because of a possible infection of the wound, he 
was treated with antibiotics.
If this patient had not received combination treatment, 
he would have been treated with FVIII concentrate mono-
therapy both before and after the dental surgery. As his 
baseline FVIII:C was 0.04 IU/mL, his body weight 100 kg 
and the target FVIII peak level was 0.80–1.00 IU/mL, the 
FVIII loading dose would be (1.00–0.04)/0.02*100=4750 
IU (rounded to entire vials). In the evening, the patient 
would have received 2500 IU to maintain the FVIII:C 
between the target FVIII. Therefore, combination treat-
ment hypothetically saved 2750 IU FVIII concentrate in 
this patient.
EthICs And dIssEMInAtIon
The study was approved. The study will be conducted 
according to good clinical practice (GCP) guidelines and 
the Declaration of Helsinki. Also, see online supplemen-
tary data 3–6 for our regulations for data storage, amend-
ments and compensation for injury. Written informed 
consent will be obtained from all patients by a member of 
the research team (see online supplementary data 7 for 
the patient information, Dutch only). Results of the study 
will be communicated to the (inter)national medical and 
scientific community trough publication in high-ranking 
peer-reviewed international journals and at (inter)
national medical scientific conferences. Results of the 
study will also be implemented in the Dutch Haemophilia 
Treatment Guidelines. Hopefully, the international 
society of Haemophilia Treatment Centres will adapt the 
results in their guidelines as well.
data monitoring committee and serious adverse events
This study does not carry any large safety risks as both 
FVIII concentrates and desmopressin are registered ther-
apeutics for haemophilia treatment. In addition, to guar-
antee safety for all patients in this study, FVIII:C levels will 
be closely monitored to prevent any additional bleeding 
risks. Therefore, a data safety monitoring board is not 
needed.
Serious adverse events (SAE) will be communicated to 
the sponsor within 24 hours. The sponsor will register the 
SAE within 15 days on ToetsingOnline, the Dutch regis-
tration system for SAEs.
rEgIstrAtIon
The trial is registered in the Dutch Trial Registry, 
number NTR5383 ( www. trialregister. nl) and in EudraCT: 
2014-00535-14.
dIsCussIon
This prospective trial will allow us to evaluate the safety 
and efficacy of combination treatment of desmopressin 
and FVIII concentrate in reaching target FVIII:C during 
bleeding episodes and in the perioperative setting. 
Figure 2 Factor VIII (FVIII):C course after desmopressin and FVIII concentrate combination treatment in a pilot patient 
with moderate haemophilia A (FVIII:C 0.04 IU/mL). Lines are the predicted FVIII:C. Predictions were based on a previous 
desmopressin test dose and FVIII concentrate administration, prior to study inclusion. Solid line is total FVIII:C and can be 
measured. Open circles are measured FVIII:C. Infusions of desmopressin and FVIII concentrate (FVIII con.) are depicted with 
arrows. T0, preoperative desmopressin infusion. 
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Dosing of FVIII concentrate will be determined by an 
integrated population PK model developed specifically 
for patients with non-severe haemophilia A to be treated 
with combination treatment. Fifty patients with non-se-
vere haemophilia A will be included from eight haemo-
philia treatment centres in the Netherlands to reach our 
aim.
The DAVID study has some limitations. First, this study 
is not designed as a randomised controlled trial; it does 
not include a control group. Therefore, no direct compar-
ison to standard treatment will be possible. However, we 
performed an extensive retrospective cohort study to 
determine the effectiveness of current clinical practice 
in which 37 patients undergoing 52 surgeries were eval-
uated.2 Moreover, the amount of FVIII concentrate that 
would have been administered to the patients included 
in the DAVID study, as if desmopressin was not adminis-
tered and as if no PK-guided dosing was applied, will be 
calculated.
The second limitation is the heterogeneity of the study 
population. All types of surgery, unless not compatible 
with desmopressin treatment, may be included in the 
study. To limit the effects of this heterogeneity, only 
patients with an expected treatment duration of at least 
48 hours will be included. Moreover, the data that were 
used to develop the integrated population PK model also 
included data from various types of surgery.
ConClusIon
In the DAVID study, efficacy and safety of desmopressin 
and FVIII concentrate combination treatment in patients 
with non-severe haemophilia A will be determined. Using 
this innovative approach treatment of patients with 
non-severe haemophilia A both during bleeding episodes 
and in the perioperative setting may be improved.
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